Biopharmas raising money in public or private financings, including: Acerus, Adamis, Agile, Akari, Algernon, Avadel, Briacell, Eyepoint, Vaxil, Xeris.

Infectious disease has been rough going for all comers the past few years, as companies have floundered. Appili Therapeutics Inc.’s CEO, Armand Balboni saw the troubles others encountered with the indication and also saw companies with thin pipelines struggle, but it hasn’t stopped him from forging on.

Med-tech firms raising money in public or private financings, including: Bausch Health Companies, Catalent, Cloudbreak Health, Q Bio.

Biopharmas raising money in public or private financings, including: Aeterna Zentaris, Alladapt, Axovant, Bioxcel, Deciphera, Hemostemix, Spruce.

Med-tech firms raising money in public or private financings, including: Catalent, Innerscope Hearing Technologies, Myomo, Pixium Vision, Veravas.

DUBLIN – Neotx Therapeutics Ltd. raised $45 million in a series C round to continue clinical development of an immuno-oncology agent that already has a long clinical history behind it. Its lead molecule, naptumomab estafenatox, is a fusion protein comprising an antibody fragment that recognizes the oncofetal antigen 5T4 and a bacterial “super-antigen” comprising a modified version of the Staphylococcal enterotoxin A.

Biopharmas raising money in public or private financings, including: Catalyst, Genprex, Mereo, Revolution.

HONG KONG – South Korea’s AI-based biotech venture, Kaipharm Co. Ltd. has secured ₩5 billion (US$4.22 million) in series A funding. Founded in 2018, the firm has attracted a total of ₩7 billion in investments. Kaipharm will generate a reference dataset of 2,000 drugs (KMAP_2K) using next-generation sequencing (NGS). The dataset will include all the FDA-approved drugs to date.